Business Context and Reporting Period
This Form 10-Q covers Cytotherapeutics, Inc. for the quarter and nine months ended September 30, 1999. The company is a biotechnology firm engaged in research and development of human therapeutic products. During this period, the company executed a major strategic restructuring, terminating its encapsulated cell technology program to focus exclusively on its proprietary stem cell technology platform. This involved terminating approximately 68 employees and relocating corporate headquarters from Rhode Island to Sunnyvale, California.
Key Financial Metrics
| Metric | Q3 1999 | Q3 1998 | 9 Months 1999 | 9 Months 1998 |
|---|---|---|---|---|
| Revenue | $0 | $2,539,557 | $5,021,707 | $6,289,120 |
| Net Loss | ($6,711,046) | ($2,867,680) | ($10,483,760) | ($10,434,590) |
| Loss Per Share (Basic/Diluted) | ($0.36) | ($0.16) | ($0.56) | ($0.57) |
| Cash & Cash Equivalents | $3,688,923 | N/A | $3,688,923 (End of Period) | $9,289,600 (End of Period) |
| Total Current Assets | $7,215,165 | N/A | $7,215,165 | N/A |
| Total Current Liabilities | $2,139,427 | N/A | $2,139,427 | N/A |
| Long-Term Debt | $0 | N/A | $0 | $500,000 |
Note: The company reported $4.1 million in "Wind-down" expenses for the quarter and nine months ended September 30, 1999, which significantly impacted operating results.
Material Changes vs. Prior Period
- Revenue Collapse: Revenue dropped to zero in Q3 1999 compared to $2.54 million in Q3 1998. This was caused by the termination of the collaborative agreement with AstraZeneca in June 1999 following failed clinical trial results for the company's encapsulated cell therapy.
- Increased Net Loss: Net loss for Q3 1999 increased by 134% to $6.71 million compared to $2.87 million in the prior year quarter, driven by the loss of revenue and the recognition of $4.1 million in restructuring costs.
- Reduced Operating Expenses: Research and Development (R&D) expenses decreased by 63% in Q3 1999 ($1.58 million vs. $4.28 million) due to the wind-down of the encapsulated cell program. General and Administrative (G&A) expenses also declined by 20%.
- Liquidity Decline: Cash and cash equivalents decreased by approximately $4.18 million during the nine-month period, primarily due to operating cash outflows of $9.75 million, partially offset by net cash provided by investing activities ($6.73 million) from the sale of marketable securities.
- Debt Reduction: The company retired its $2 million credit facility in August 1999, resulting in zero long-term debt as of September 30, 1999.
Outlook, Risks, and Contingencies
- Liquidity Outlook: Management expects existing capital resources, investment income, and proceeds from asset sales to fund operations only into the first quarter of 2000. The company requires significant additional capital to sustain its stem cell research.
- Asset Disposition: The company is negotiating the sale or license of its encapsulated cell technology intellectual property and excess fixed assets. Proceeds are critical for funding future operations, but success is not assured.
- Legal Contingency (RIPSAT): The Rhode Island Partnership for Science and Technology (RIPSAT) has alleged default under a 1989 funding agreement and demanded payment of approximately $2.6 million. The company contests the default but is engaged in settlement discussions. A settlement could materially adversely affect liquidity.
- Genentech Redemption: Genentech terminated a Parkinson's disease collaboration in 1998 and demanded redemption of shares held by Genentech. The filing notes this could have a material adverse effect on liquidity if executed.
- Facility Obligations: The company faces substantial ongoing obligations for its Rhode Island facilities (approximately $1.95 million annually in lease and debt service) while attempting to sublease or sell these assets.
Investor Verification Checklist
- Runway Confirmation: Verify the company's ability to secure financing or asset sale proceeds before Q1 2000 to avoid insolvency.
- RIPSAT Dispute Resolution: Monitor the status of the $2.6 million demand from RIPSAT and the likelihood of a settlement versus litigation.
- Asset Sale Progress: Track negotiations regarding the sale of the Rhode Island pilot manufacturing plant and the licensing of encapsulated cell IP.
- Genentech Redemption: Confirm if and when the redemption of Genentech's shares will occur and the immediate cash impact.
- Stem Cell Funding: Assess the company's progress in securing new collaborative partners specifically for its stem cell technology platform.